Reports Summarize B-Cell Lymphoma Findings from Zhejiang Hospital (Histone Deacetylase Inhibitor and Pd-1 Blockade Synergistically Inhibit B-cell Lymphoma Progression In Mice Model By Promoting T-cell Infiltration and Apoptosis).

A recent study conducted at Zhejiang Hospital in China explored a potential therapeutic strategy for B-cell lymphoma. The study focused on combining a histone deacetylase inhibitor (romidepsin) with PD-1 blockade (BMS-1) in a mouse model of B-cell lymphoma. The results showed that the combined treatment of romidepsin and BMS-1 synergistically inhibited the growth of B-cell lymphoma and triggered apoptosis. Additionally, the treatment activated tumor-infiltrating lymphocytes, particularly CD3+CD4+ and CD3+CD8+ T cells. The study suggests that the combination of HDAC inhibition and PD-1 blockade could be a promising approach for treating B-cell lymphoma and enhancing antitumor immunity. [Extracted from the article]